Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

: Despite all scientific efforts and many protracted and expensive clinical trials, no new drug has been approved by FDA for treatment of Alzheimer disease (AD) since 2003. Indeed, more than 200 investigational programs have failed or have been abandoned in the last decade. The most probable explanations for failures of disease-modifying treatments (DMTs) for AD may include late initiation of treatments during the course of AD development, inappropriate drug dosages, erroneous selection of treatment targets, and mainly an inadequate understanding of the complex pathophysiology of AD, which may necessitate combination treatments rather than monotherapy. Clinical trials' methodological issues have also been criticized. Drug-development research for AD is aimed to overcome these drawbacks. Preclinical and prodromal AD populations, as well as traditionally investigated populations representing all the clinical stages of AD, are included in recent trials. Systematic use of biomarkers in staging preclinical and prodromal AD and of a single primary outcome in trials of prodromal AD are regularly integrated. The application of amyloid, tau, and neurodegeneration biomarkers, including new biomarkers-such as Tau positron emission tomography, neurofilament light chain (blood and Cerebrospinal fluid (CSF) biomarker of axonal degeneration) and neurogranin (CSF biomarker of synaptic functioning)-to clinical trials allows more precise staging of AD. Additionally, use of Bayesian statistics, modifiable clinical trial designs, and clinical trial simulators enrich the trial methodology. Besides, combination therapy regimens are assessed in clinical trials. The above-mentioned diagnostic and statistical advances, which have been recently integrated in clinical trials, are relevant to the recent failures of studies of disease-modifying treatments. Their experiential rather than theoretical origins may better equip potentially successful drug-development strategies.

What this study adds

Evidence grade: Low

This is a narrative review. This paper attributes past failures of disease-modifying treatments to factors such as late treatment initiation, inappropriate dosages, wrong targets and inadequate understanding of the disease, and notes that combination treatments may be needed. It describes changes to trial design and biomarker use, but reports no approved new treatment.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., & Pelidou, S. H. (2019). Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. Biomedicines. https://doi.org/10.3390/biomedicines7040097

Vancouver

Yiannopoulou KG, Anastasiou AI, Zachariou V, Pelidou SH. Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. Biomedicines. 2019. doi:10.3390/biomedicines7040097. PMID: 31835422.

BibTeX

@article{yiannopoulou2019-31835422,
  author  = {Yiannopoulou, K. G. and Anastasiou, A. I. and Zachariou, V. and Pelidou, S. H.},
  title   = {{Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research}},
  journal = {Biomedicines},
  year    = {2019},
  doi     = {10.3390/biomedicines7040097},
  pmid    = {31835422},
  url     = {https://doi.org/10.3390/biomedicines7040097}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This paper attributes past failures of disease-modifying treatments to factors such as late treatment initiation, inappropriate dosages, wrong targets and inadequate understanding of the disease, and notes that combination treatments may be needed. It describes changes to trial design and biomarker use, but reports no approved new treatment.

Study details

How this study scored 49/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 49 of 100.49 of 100 points earned51 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Biomedicines)
Journal's citation record 1 / 4 Biomedicines: journal h-index 133 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2019 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 333 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 37.0 citations a year over 9 year(s) since 2019
Impact for its field and year 4 / 6 Cited 19.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 9 other studies in this library
Still being cited 3 / 4 Cited 151 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Sigliti‐Henrietta Pelidou: h-index 23 (OpenAlex, whole career)
Institution's track record 1 / 3 Icahn School of Medicine at Mount Sinai: institution h-index 1,331 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 31835422)
Free to read 2 / 2 Free to read
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.

Later studies that cite this one

9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Biomarkers from nearby years

Also in Biomarkers

139 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.

Similar studies

More on Biomarkers

See all studies in Biomarkers →